Development of Medical Countermeasures for Biodefense and Emerging Infectious Diseases

The National Institutes of Health is forecasting a contract opportunity for the development of medical countermeasures targeting biodefense threats and emerging infectious diseases, with a NAICS code of 541714 indicating research and development in the physical, engineering, and life sciences. The opportunity is open to qualified entities capable of advancing novel therapeutics, vaccines, diagnostics, or other interventions to address high-priority biological threats and newly emerging pathogens, with an emphasis on capabilities that can be rapidly scaled and deployed in public health emergencies. The point of contact for program-related inquiries is Paul Eder, while Alexandra Buck serves as the contracting officer for administrative and procurement matters. This forecasted procurement is not a solicitation but rather an indicator of the agency’s future intent to award a contract, allowing industry to prepare responsive proposals well in advance of the formal request for proposals. The place of performance and specific set-aside status are not yet defined, suggesting the contract may be awarded broadly without geographic or small business restrictions at this stage. Interested parties are encouraged to monitor the official HHS OSDBU portal for upcoming solicitations, as the official solicitation will provide detailed technical requirements, evaluation criteria, and submission deadlines.